The decision made with regard to these NICE 30 day TAs can now be found at:

  • TA918 – Bimekizumab for treating axial spondyloarthritis
  • TA920 – Tofacitinib for treating active ankylosing spondylitis
  • TA925 – Mirikizumab for treating moderately to severely active ulcerative colitis
  • TA927 Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments